⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 17, 2016VaccineOpen Access

Gavi’s policy steers country ownership and self-financing of immunization

Klara Henderson Dimitrios Gouglas Laura Craw

View Full Paper

Ask AI

Bookmark

Share

Abstract

This commentary examines the 2014 NIPH evaluation of Gavi's co-financing policy and comments on the appropriateness of the subsequent and most significant policy changes taking effect in 2016.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Henderson et al. (2016) studied this question.

synapsesocial.com/papers/6a9668aa1f16343146bb7638 https://doi.org/10.1016/j.vaccine.2016.06.014

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Creating Sustainable Financing And Support For Immunization Programs In Fifteen Developing CountriesOriginal Research · 2011 · 24 citations
2Differences between Canadian parents’ attitudes toward routine, influenza, and COVID-19 vaccines for their children, and changes in vaccine hesitancy since the pandemic: A national cross-sectional comparative studyVaccine · 2026
3A qualitative examination of factors impacting Black and Latino sexual minority men's vaccination decision-making and experiences: application of the stages of vaccine readiness and action theoretical frameworkVaccine · 2026
4Exploring perceptions of 4CMenB vaccination for gonorrhoea prevention among gay, bisexual and other men who have sex with men and healthcare professionals in England: a qualitative focus group studyVaccine · 2026
5Boosting hybrid immunity with intranasal live-attenuated or intramuscular mRNA vaccination prevents SARS-CoV-2 XBB.1.5 transmissionVaccine · 2026

Exposure to natural disasters and vaccination indicators: a systematic review and directions for future researchVaccine · 2026
Faster waning of immunity to influenza vaccine strains reintroduced into subsequent seasons: A human cohort studyVaccine · 2026
Monitoring of adverse events following 2024–2025 BNT162b2 KP.2 COVID-19 vaccination in the United StatesVaccine · 2026
Hemagglutinin- and neuraminidase-targeting antibody responses after receipt of egg-based inactivated or recombinant influenza vaccines among adults aged 18–64 yearsVaccine · 2026
mRNA encoding norovirus VP1 produces antigenically functional virus-like particles in vitroVaccine · 2026

More from Vaccine

More from Norwegian Institute of Public Health